<DOC>
	<DOC>NCT01767766</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.</brief_summary>
	<brief_title>Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<criteria>Refractory to or relapsed after at least 1 prior treatment regimen; Eastern Cooperative Oncology Group (ECOG) score of 0 to 2; At least 18 years of age. Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed â‰¥ 2 weeks); Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months; Known hepatitis B virus, hepatitis C virus or HIV infection; Previous therapy with GS1101 (CAL101), IPI145 or any drug that specifically inhibits the PI3K or mTOR pathway;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>